Randomized Controlled Trial
Copyright ©The Author(s) 2017.
World J Gastroenterol. Nov 7, 2017; 23(41): 7470-7477
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7470
Table 1 Baseline characteristics of the study population
CharacteristicSMA group (n = 20)TIPS group (n = 20)P value
Age (yr)148.4 ± 13.250.1 ± 8.60.632
Male sex14151.0003
Etiology0.1563
HBV1417
HCV01
Alcohol51
Autoimmune01
Cryptogenic10
Child-Pugh class0.0652
A61
B89
C610
Child-Pugh score18.6 ± 1.79.4 ± 1.80.135
MELD score18.0 ± 6.99.1 ± 5.10.582
Splenectomy630.4513
Past esophageal or gastric varices13180.1273
Past gastrointestinal bleeding12180.0653
MPV thrombus0.9382
Grade I67
Grade II1311
Grade III12
SMV thrombus1150.1053
SV thrombus871.0003
Table 2 Comparison of portal vein thrombosis changes between the two groups
SMA group (n = 20)TIPS group (n = 20)
Time (mo)6122461224P value
Recanalization1515131213110.239 (6 mo)
Improved4444230.307 (12 mo)
Stable1134220.304 (24 mo)
Worse000034
Table 3 Changes in portal vein thrombosis before and after urokinase infusion in the superior mesenteric artery group
BeforeAfterP value
MPV thrombus< 0.001
Grade 0013
Grade I64
Grade II133
Grade III10
SMV thrombus1140.0481
SV thrombus810.021
Table 4 Changes in portal vein thrombosis before and after transjugular intrahepatic portosystemic shunt in the transjugular intrahepatic portosystemic shunt group
BeforeAfterP value
MPV thrombus< 0.001
Grade 0011
Grade I73
Grade II112
Grade III24
SMV thrombus570.7311
SV thrombus730.2731